Viking Therapeutics announces full exercise of over-allotment option
Viking Therapeutics announced that the underwriters for its recent initial public offering have exercised in full their option to purchase from Viking an additional 450,000 shares at the initial offering price to the public of $8.00 per share. Gross proceeds were $27.6 million. May 29, 2015